STOCK TITAN
  1. Home
  2. News
  3. TWST

Twist Bioscience Corp - TWST STOCK NEWS

Welcome to our dedicated news page for Twist Bioscience (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Twist Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Twist Bioscience's position in the market.

News
Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will issue its financial results for the fiscal 2024 first quarter on February 2, 2024. The company plans to hold a conference call and live audio webcast to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website. The conference call will be webcast live and the webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences earnings
-
News
Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 50,000 restricted stock units and 70,000 shares to its chief financial officer, Adam Laponis, as an inducement material to his acceptance of employment with Twist. The RSUs vest quarterly over a 48-month period, with the first 25% vesting on the one-year anniversary of Mr. Laponis' employment. The shares subject to the executive compensation programs include RSUs and performance stock units that vest based on achievement against established metrics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
News
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
Rhea-AI Summary
Twist Bioscience Corporation (TWST) appoints Adam Laponis as chief financial officer. Mr. Laponis brings extensive experience from Eargo, Inc., Tesla, Inc., and Cardinal Health, with a track record of driving profitable growth and increasing revenue. His appointment is expected to drive value for stakeholders and contribute to the company's growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
management
News
Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8. The presentation will be webcast live and can be accessed through the company's investor relations section. A replay will be archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
News
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $245.1 million in Fiscal 2023, a 20% increase over 2022. Orders also grew to $264 million, up 17% from 2022. Fiscal 2024 revenue is expected to range between $285 million to $290 million. The company's CEO, Dr. Emily M. Leproust, expressed optimism for the future, focusing on profitability and growth for the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
earnings
-
News
Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) Launches Twist Express Genes, a new gene synthesis service with a turnaround time of five to seven business days. The service is enabled by the state-of-the-art Wilsonville manufacturing facility, offering high-quality synthetic DNA using its silicon platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.96%
Tags
none
News
Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces participation in the 6th Annual Evercore ISI HealthCONx Conference. CEO Emily M. Leproust and CFO Jim Thorburn will engage in a fireside chat on November 28 at 7:30 a.m. Eastern Time in Miami, FL. The webcast will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
News
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces grant of 130,400 restricted stock units to 15 new hires. The RSUs vest over a 48-month period, in accordance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
-
News
Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for the fiscal 2023 fourth quarter and full year on November 17, 2023. The company will hold a conference call and live webcast at 8:00 a.m. Eastern Time to discuss the results and provide a business update. The press release and webcast will be accessible from the company's website. Telephone participants must register in advance to receive the dial-in number and PIN. Webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
conferences earnings
News
Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing
Rhea-AI Summary
Twist Bioscience launches Twist Full Length Unique Dual Index Adapters for PCR-free whole genome sequencing and multiplexing. The adapters streamline library preparation, reduce hands-on time, and eliminate PCR-related errors. They come with 1536 barcoded indexes for tracking individual samples, allowing researchers to run up to 1536 samples in a single sequencing run. Twist will showcase the new offering at the ASHG 2023 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
Stock TWST logo
Twist Bioscience Corp

Nasdaq:TWST

TWST Rankings

#2020 Ranked by Market Cap
#4771 Ranked by Stock Gains
N/A Ranked by Dividends

TWST Stock Data

1.77B
56.87M
1.78%
113.36%
21.2%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About TWST

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .